Epigenetic silencing of the O-6-methylguanine-DNA methyltransferase (MGMT) gene by promoter methylation is associated with prolonged survival and sensitivity to chemotherapeutic alkylating agents in GBM patients undergoing standard treatment [23, 24]. This evidence concerns the gene MGMT and glioblastoma.